Pharsight

Steglatro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8080580 MSD SUB MERCK Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(6 years from now)

Steglatro is owned by Msd Sub Merck.

Steglatro contains Ertugliflozin.

Steglatro has a total of 1 drug patent out of which 0 drug patents have expired.

Steglatro was authorised for market use on 19 December, 2017.

Steglatro is available in tablet;oral dosage forms.

Steglatro can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Drug patent challenges can be filed against Steglatro from 19 December, 2021.

The generics of Steglatro are possible to be released after 13 July, 2030.

Drug Exclusivity Drug Exclusivity Expiration
M(M-275) Sep 17, 2024
New Chemical Entity Exclusivity(NCE) Dec 19, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ERTUGLIFLOZIN ingredient

NCE-1 date: 19 December, 2021

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

How can I launch a generic of STEGLATRO before it's drug patent expiration?
More Information on Dosage

STEGLATRO family patents

Family Patents